Intelligence Platform

Patents

Browse 429 pharma-relevant patents (US and EP, A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed

patent

US 11219692

Porphyrin modified telodendrimers

The Regents of the University of California · Granted Tue Jan 11 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 06 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11208655

Functionally-modified oligonucleotides and subunits thereof

Sarepta Therapeutics, Inc. · Granted Tue Dec 28 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 23 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11203749

Factor VII polypeptides that are modified and uses thereof

Catalyst Biosciences, Inc. · Granted Tue Dec 21 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 16 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11186822

Genetically-modified immune cells comprising a microRNA-adapted shRNA (shRNAmiR)

Precision BioSciences, Inc. · Granted Tue Nov 30 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 25 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11174292

Substitutions-modified prefusion RSV F proteins and their use

The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Nov 16 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 11 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11166960

Modified release preparations containing oxcarbazepine and derivatives thereof

Supernus Pharmaceuticals, Inc. · Granted Tue Nov 09 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 04 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11161908

BAFF-R targeted chimeric antigen receptor-modified t-cells and uses thereof

The Board of Regents of the University of Texas System · Granted Tue Nov 02 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 28 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11147837

Modified cells and methods of therapy

The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Oct 19 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 14 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11135280

Modified ebolavirus glycoproteins comprising mutations in the head and base domains that i

INTEGRATED BIOTHERAPEUTICS, INC. · Granted Tue Oct 05 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 30 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11129794

Chemically modified small molecules

Nektar Therapeutics · Granted Tue Sep 28 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 23 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11098283

T cells modified to overexpress c-Myb

The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Aug 24 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 19 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11091555

Method of treating gastric cancer with anti-FGFR2-IIIb antibodies and modified FOLFOX6 che

Five Prime Therapeutics, Inc. · Granted Tue Aug 17 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 12 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11084844

Modified nucleosides, analogs thereof and oligomeric compounds prepared therefrom

Ionis Pharmaceuticals, Inc. · Granted Tue Aug 10 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 05 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11078227

5′-cyclo-phosphonate modified nucleotides

Arrowhead Pharmaceuticals, Inc. · Granted Tue Aug 03 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 29 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11078485

Compositions comprising alternating 2′-modified nucleosides for use in gene modulation

Ionis Pharmaceuticals, Inc. · Granted Tue Aug 03 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 29 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11051499

Genetically modified mice and engraftment

REGENERON PHARMACEUTICALS, INC. · Granted Tue Jul 06 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 01 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11053290

Modified Tamm-Horsfall protein and related compositions and methods of use

The United States Government as Represented by the Department of Veterans Affair · Granted Tue Jul 06 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 01 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11053484

Genetically-modified T cells comprising a modified intron in the T cell receptor alpha gen

Precision BioSciences, Inc. · Granted Tue Jul 06 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 01 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11008548

Genetically-modified immune cells comprising a microRNA-adapted shRNA (shRNAmiR)

Precision BioSciences, Inc. · Granted Tue May 18 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 13 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10995156

Acid-degradable and bioerodible modified polyhydroxylated materials

The Regents of the University of California · Granted Tue May 04 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 29 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10993419

Genetically modified cells, tissues, and organs for treating disease

Regents of the University of Minnesota · Granted Tue May 04 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 29 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10982203

Modified factor IX polypeptides and uses thereof

Catalyst Biosciences, Inc. · Granted Tue Apr 20 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 15 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10954498

Modified cascade ribonucleoproteins and uses thereof

Caribou Biosciences, Inc. · Granted Tue Mar 23 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 18 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10954501

Nucleic acid encoding modified membrane type serine protease 1 (MTSP-1) polypeptides and m

Catalyst Biosciences, Inc. · Granted Tue Mar 23 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 18 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted